NEW YORK, NY / ACCESSWIRE / August 22, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
LOTZ Shareholders Click Here: https://www.zlk.com/pslra-1/carlotz-inc-loss-submission-form?prid=18813&wire=1
ANVS Shareholders Click Here: https://www.zlk.com/pslra-1/annovis-bio-inc-loss-submission-form?prid=18813&wire=1
ATIP Shareholders Click Here: https://www.zlk.com/pslra-1/ati-physical-therapy-inc-f-k-a-fortress-value-acquisition-corp-ii-loss-submission-form?prid=18813&wire=1
* ADDITIONAL INFORMATION BELOW *
![Levi & Korsinsky, LLP, Sunday, August 22, 2021, Press release picture](https://www.accesswire.com/users/newswire/images/660836/Rotating-Logo.jpg)
CarLotz, Inc. (NASDAQ:LOTZ)
LOTZ Lawsuit on behalf of: investors who purchased December 30, 2020 - May 25, 2021
Lead Plaintiff Deadline : September 7, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/carlotz-inc-loss-submission-form?prid=18813&wire=1
According to the filed complaint, during the class period, CarLotz, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) due to a surge in inventory during the second half of fiscal 2020, CarLotz was experiencing a "logjam" resulting in slower processing and higher days to sell; (2) as a result, the Company's gross profit per unit would be negatively impacted; (3) to minimize returns to the corporate vehicle sourcing partner responsible for more than 60% of CarLotz's inventory, the Company was offering aggressive pricing; (4) as a result, CarLotz's gross profit per unit forecast was likely inflated; (5) this Company's corporate vehicle sourcing partner would likely pause consignments to the Company due to market conditions, including increasing wholesale prices; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Annovis Bio, Inc. (NYSE:ANVS)
ANVS Lawsuit on behalf of: investors who purchased May 21, 2021 - July 28, 2021
Lead Plaintiff Deadline : October 18, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/annovis-bio-inc-loss-submission-form?prid=18813&wire=1
According to the filed complaint, during the class period, Annovis Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Annovis's ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
ATI Physical Therapy, Inc. f/k/a Fortress Value Acquisition Corp. II (NYSE:ATIP)
This lawsuit is on behalf of investors who: (a) purchased or otherwise acquired ATI securities between April 1, 2021 and July 23, 2021, inclusive and/or (b) held FVAC Class A common stock as of May 24, 2021 and were eligible to vote at FVAC's June 15, 2021 special meeting.
Lead Plaintiff Deadline : October 15, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ati-physical-therapy-inc-f-k-a-fortress-value-acquisition-corp-ii-loss-submission-form?prid=18813&wire=1
According to the filed complaint, (1) ATI was experiencing attrition among its physical therapists; (2) ATI faced increasing competition for clinicians in the labor market; (3) as a result of the foregoing, the Company faced difficulties retaining therapists and incurred increased labor costs; (4) as a result of the labor shortage, the Company would open fewer new clinics; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP